- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Cervical intraepithelial neoplasia.
Displaying page 1 of 3.
EudraCT Number: 2008-007763-16 | Sponsor Protocol Number: 1.0 | Start Date*: 2009-05-06 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006946-24 | Sponsor Protocol Number: NV25025 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high... | ||||||||||||||||||
Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2010-023271-26 | Sponsor Protocol Number: MI-CI-C02 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:Mithra Pharmaceuticals SA | |||||||||||||
Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl... | |||||||||||||
Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003507-19 | Sponsor Protocol Number: HOPE9 | Start Date*: 2020-09-10 | |||||||||||||||||||||
Sponsor Name:AZIENDA USL TOSCANA NORD OVEST | |||||||||||||||||||||||
Full Title: “Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diat... | |||||||||||||||||||||||
Medical condition: Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003177-42 | Sponsor Protocol Number: COHEAHR-WP4 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:Catalan Institute of Oncology | ||||||||||||||||||
Full Title: Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 30 to 45 years | ||||||||||||||||||
Medical condition: Cervical cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) ES (Completed) BE (Completed) FI (Completed) SI (Completed) NL (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001169-34 | Sponsor Protocol Number: HPV_Elimination | Start Date*: 2021-03-24 | ||||||||||||||||
Sponsor Name:Region Stockholm [...] | ||||||||||||||||||
Full Title: Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden | ||||||||||||||||||
Medical condition: HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000318-12 | Sponsor Protocol Number: MITOCERV3 | Start Date*: 2020-02-20 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer | |||||||||||||
Medical condition: Locally advanced cervical cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004604-31 | Sponsor Protocol Number: PCCE201/08 | Start Date*: 2008-10-28 | |||||||||||
Sponsor Name:Photocure ASA | |||||||||||||
Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia. | |||||||||||||
Medical condition: Low grade cervical intraepithelial neoplasia (CIN) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002035-26 | Sponsor Protocol Number: 115411 | Start Date*: 2011-10-21 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||
Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ... | |||||||||||||||||||||||
Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) SE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005576-28 | Sponsor Protocol Number: VB-C-01 | Start Date*: 2015-07-13 |
Sponsor Name:VACCIBODY A.S. | ||
Full Title: An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3) | ||
Medical condition: High grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002247-23 | Sponsor Protocol Number: MITOCERV4 | Start Date*: 2020-01-29 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: Single arm phase II study on Pembrolizumab in preneoplastic high grade HPV-related vulvar and cervical lesions | ||||||||||||||||||
Medical condition: Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023903-91 | Sponsor Protocol Number: PCCE203/10 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Photocure ASA | |||||||||||||
Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2). | |||||||||||||
Medical condition: Patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001342-19 | Sponsor Protocol Number: YHGT-CEV-R1 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Asieris MediTech Co., Ltd. | |||||||||||||
Full Title: A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepit... | |||||||||||||
Medical condition: Patients with cervical histologic HSIL. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) SK (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003944-23 | Sponsor Protocol Number: UFK-HEF 5 | Start Date*: 2005-04-20 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Acetyl salicylic acid in the treatment of patients with positive margins after surgery for cervical dysplasia grade II-III: A phase II trial | ||
Medical condition: Cervical intraepithelial neoplasia grade II/III with positive margin after surgery | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-004721-40 | Sponsor Protocol Number: HPV-EU-001 | Start Date*: 2015-04-22 | |||||||||||
Sponsor Name:Genexine, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularl... | |||||||||||||
Medical condition: Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), Grade 2/3 (CIN 2/3) or Grade 3 (CIN3) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004933-14 | Sponsor Protocol Number: V502-003-01 | Start Date*: 2006-11-13 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L... | |||||||||||||
Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002308-10 | Sponsor Protocol Number: TOPIC-2 | Start Date*: 2015-10-20 |
Sponsor Name: | ||
Full Title: A randomized, single blinded trial to evaluate the efficacy of Imiquimod in women with residual/recurrent Cervical Intraepithelial Neoplasia (CIN) after previous treatment | ||
Medical condition: Residual or recurrent Cervical Intraepithelial Neoplasia (CIN) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002096-96 | Sponsor Protocol Number: NL57849.068.16 | Start Date*: 2016-09-20 |
Sponsor Name:Maastricht University Medical Center | ||
Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia, a multicenter, open-label, non-randomized, controlled study (TOPIC-3 study) | ||
Medical condition: High-grade Cervical Intraepithelial Neoplasia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004114-17 | Sponsor Protocol Number: HPV-303 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... | ||||||||||||||||||
Medical condition: HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) EE (Completed) ES (Restarted) PL (Completed) FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001260-34 | Sponsor Protocol Number: 414520 | Start Date*: 2014-09-09 |
Sponsor Name:Maastricht University Medical Center | ||
Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): a randomized controlled trial | ||
Medical condition: High grade cervical intraepithelial neoplasia. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
